Another stock that insiders are loading up on here is Genomic Health (GHDX), which is engaged in the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. Insiders are buying this stock into weakness, since shares are off by 16.5% in the last six months.
Genomic Health has a market cap of $876 million and an enterprise value of $779 million. This stock trades at a premium valuation, with a trailing price-to-earnings of 110.19 and a forward price-to-earnings of 98.79. Its estimated growth rate for this year is -84.6%, and for next year it's pegged at 625%. This is a cash-rich company, since the total cash position on its balance sheet is $99.07 million and its total debt is zero.A director and beneficial owner just bought 116,360 shares, or about $3.27 million worth of stock, at $27.96 to $28.23 per share. From a technical perspective, GHDX is currently trending above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock has been trading inside of a consolidation pattern for the last month, with shares moving between $27.56 on the downside and $30.18 on the upside. A high-volume move above the upper-end of that recent sideways chart pattern will trigger a near-term breakout trade for shares of GHDX. If you're in the bull camp on GHDX, then I would look for long-biased as long as it's trending above $27.56 or $26.78, and then once it manages to break out above some near-term overhead resistance levels at $29.54 to $30.18 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 222,634 shares. If that breakout triggers soon, then GHDX will set up to re-fill some of its previous gap down zone from last November that started near $32 a share. Any high-volume move above $33 will then put $35 to $36 into range for shares of GHDX.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV